In 40 seconds
Bone density loss — osteopenia and the more advanced osteoporosis — affects an estimated 3.5 million people in the UK and is the leading cause of fragility fractures of the hip, spine and wrist. PEMF therapy has the longest evidence base of any PEMF application: FDA-cleared for non-union fractures since 1979, with a growing body of clinical evidence for postmenopausal osteoporosis, fracture healing, and joint replacement integration. PEMF is an adjunct to standard care — calcium, vitamin D, weight-bearing exercise, and bisphosphonates or other bone-active medications where prescribed — not a replacement for DEXA-guided treatment.
Quick facts
- FDA-cleared since: 1979 (non-union fractures, OL1000 device)
- UK applicability: Adjunct to NICE-aligned osteoporosis care
- Best evidence for: Non-union fractures, postmenopausal bone loss, post-fracture recovery
- Standard UK care: DEXA scan, calcium + vit D, weight-bearing exercise, bisphosphonates per FRAX risk
- Sessions: 30–40 minutes, 3–5× per week for 6–12 weeks
- Speak to first: Your GP and a DEXA scan if you're at risk
Why bone health matters in the UK
The Royal Osteoporosis Society estimates that 3.5 million people in the UK have osteoporosis, with one in two women and one in five men over 50 sustaining a fragility fracture. The bones at greatest risk are the hip, vertebrae and distal radius (wrist).
Standard care follows NICE guideline NG28 / NG143 and the FRAX risk calculator: DEXA scan to measure bone mineral density, calcium and vitamin D supplementation, weight-bearing exercise, and bisphosphonates (alendronate, risedronate, zoledronate) or other bone-active medications when fracture risk warrants.
PEMF therapy slots in as a non-pharmacological adjunct. It does not replace bisphosphonates, but a growing body of evidence suggests it can complement them — particularly in patients who are intolerant of, or unable to take, the standard medications.
How PEMF affects bone biology
Bone is dynamic tissue. Osteoblasts build new bone; osteoclasts break it down. The balance between these two cell populations determines whether bone density rises or falls. In osteoporosis, osteoclast activity outpaces osteoblast activity for years, producing the gradual thinning that ends in fragility fracture.
PEMF therapy influences this balance through several documented mechanisms:
- Osteoblast stimulation — pulsed magnetic fields appear to up-regulate osteoblast proliferation and matrix production. Multiple in-vitro studies and animal models show this effect.
- Osteoclast modulation — PEMF appears to reduce osteoclast activity in osteoporotic models, shifting the bone remodelling balance towards formation.
- Calcium uptake into bone — PEMF has been shown to enhance calcium-channel activity in bone-forming cells, supporting better mineralisation.
- Improved local microcirculation — better blood flow to bone supports nutrient delivery and waste clearance, both of which favour healthy bone turnover.
- Anti-inflammatory effect — chronic low-grade inflammation contributes to bone loss; PEMF down-regulates the relevant cytokines (TNF-α, IL-6).
This is why bone has the longest PEMF track record. The cellular mechanisms map cleanly onto the clinical outcomes that matter: faster fracture healing, fewer non-unions, and modest gains in bone mineral density on DEXA.
Typical UK protocol
| Use case | Frequency | Course length | Goal |
|---|---|---|---|
| Non-union fracture | Daily (1× per day) | 3–9 months | Stimulate bone bridging at the non-union site |
| Acute fracture support | 3–5× per week | 6–12 weeks | Faster callus formation, return to function |
| Osteopenia / osteoporosis | 3× per week | 12 weeks initial, then 1–2× per week | Modest BMD gain on DEXA at 6–12 months |
| Post-joint replacement | 2–3× per week | 4–8 weeks post-op | Implant integration, faster mobility |
Bone responds slowly. Don't expect to feel anything during a session — bone is not pain-sensitive in the way muscles or skin are. The metric that matters is the next DEXA scan (typically 12–24 months after starting) and freedom from fragility fracture.
What the evidence shows
Bone is the most-studied PEMF application. Useful pointers from the literature:
- Non-union fractures: FDA cleared the OL1000 device in 1979 on the basis of strong clinical evidence. Multiple subsequent reviews confirm 70–80% bony union rates in fractures that had previously failed to heal — a remarkable result given the difficulty of the indication.
- Postmenopausal osteoporosis: small randomised trials report modest but measurable BMD increases at the lumbar spine and hip after 6–12 months of regular PEMF, particularly when combined with calcium, vitamin D and weight-bearing exercise.
- Acute fracture healing: meta-analyses suggest faster radiographic union and earlier return to function, particularly for tibial and metatarsal fractures.
- Post-joint replacement (THR/TKR): evidence is encouraging for accelerated implant integration and reduced post-operative pain in the first 6 weeks.
The honest UK position: PEMF is the most evidence-supported PEMF indication. It does not replace bisphosphonates or weight-bearing exercise — but it has a stronger body of evidence than most "alternative" bone therapies, and it is increasingly available in UK private clinics.
Practical advice before booking
- Get a DEXA scan first — you need a baseline T-score before you can judge whether anything is working. Repeat at 12–24 months.
- Calcium + vitamin D first, PEMF second — UK guidance is 1,000 mg calcium and 800 IU vitamin D daily for adults at risk. PEMF on top of an inadequate baseline is poor value.
- Don't stop your bisphosphonate — if your GP has prescribed alendronate, risedronate or zoledronate based on FRAX risk, keep taking it. PEMF is additional, not alternative.
- Weight-bearing exercise is the foundation — bone responds to load. PEMF amplifies that response, but cannot replace it.
- If you have spinal cord stimulator or pacemaker, PEMF is a hard exclusion — see contraindications below.
Related guides on PEMF UK
PEMF for post-surgical recovery
Including hip and knee replacement integration.
Sports injuryPEMF for stress fractures
Common in runners and military personnel — the evidence overlaps with non-union work.
HistoryThe history of PEMF
FDA clearance for bone in 1979 — how PEMF became a recognised orthopaedic adjunct.
Contraindications
Hard exclusions — do not have PEMF if any apply:
- Pacemaker, implantable cardioverter-defibrillator (ICD), or any cardiac electronic device
- Cochlear implant or other implanted electronic hearing device
- Spinal cord stimulator, deep-brain stimulator, vagus nerve stimulator
- Intrathecal pump or implanted drug pump
- Insulin pump (continuous glucose monitors are usually fine — confirm with the clinic)
- Active infection at the treatment site
- Pregnancy — when treatment would be over the abdomen, lumbar spine, or pelvis
Discuss with your GP or specialist before booking if any apply:
- Active malignancy or recent cancer history (oncologist clearance required)
- History of seizures or epilepsy
- Multiple sclerosis or other neurological condition under specialist care
- Anticoagulant therapy (PEMF itself does not thin blood, but bruising risk if local circulation is already compromised)
- Children under 14 (most UK clinics will not treat under-18s without paediatric specialist input)
- Recent surgery within the last 14 days at the treatment site (confirm with surgeon)
NOT contraindications — these are commonly misunderstood:
- Plates, rods, screws and other passive metal orthopaedic hardware
- Dental implants and dental crowns
- Joint replacements (hip, knee, shoulder)
- IUDs (copper or hormonal)
- Tattoos and piercings (jewellery should be removed for the session)
Specific to this condition: If you take bisphosphonates (alendronate, risedronate, zoledronate) or denosumab for osteoporosis, continue them as prescribed. PEMF is an adjunct, not a replacement. If you have a recent fragility fracture, confirm with your fracture liaison service before starting PEMF.
Frequently asked questions
Does PEMF treat osteoporosis?
PEMF is a non-pharmacological adjunct studied for bone density support and fracture healing. It does not replace bisphosphonates or other bone-active medications prescribed on the basis of your FRAX risk. The strongest evidence is for non-union fractures, with growing evidence for postmenopausal bone loss.
Is PEMF FDA-approved for bone?
Yes — PEMF (specifically the OL1000 device) was FDA-cleared in 1979 for non-union fractures, the longest unbroken track record in PEMF medicine. It is not yet a NICE-recommended treatment for osteoporosis in the UK, but is widely available in private clinics.
How long before I see DEXA changes?
Bone remodels slowly. A DEXA scan repeat at 12 months is the earliest realistic measure; 18–24 months is more typical. Don't expect rapid change — bone gains of 1–3% per year on top of standard care are reported in the better studies.
Can I have PEMF after a fragility fracture?
Generally yes, and the evidence is encouraging for faster healing — but confirm with your fracture liaison service first. Some clinicians prefer to wait until initial fracture stabilisation has happened (typically 1–2 weeks).
Should I stop my bisphosphonate to start PEMF?
No. PEMF is additional to bisphosphonates, not an alternative. The two work through different mechanisms and the combination is reasonable. Any change to your bisphosphonate should be a decision with your GP based on DEXA, FRAX and side-effects.
What's the UK cost?
Typical UK private clinic pricing is £40–£90 per session, with 12-week packages running £600–£1,000. Bone work usually requires more sessions than soft-tissue work, so packages are key for affordability.
Find a PEMF clinic near you
We list every credible PEMF therapy provider in the UK so you can find one near home.